International Journal of Endocrinology / 2018 / Article / Tab 4

Research Article

Gender-Specific Risk of Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma

Table 4

Univariate analysis of the correlation between clinical factors of the primary tumor and rate of CLNM in male and female PTC patients.

CLNM ()MaleCLNM ()Female
NCLNM ()NCLNM ()

Age at diagnosis, M (range)37 (9–78)47 (26–66)<0.00138 (12–79)47 (13–84)<0.001
Age (<45 y/≥45 y)73/35
67.6%/32.4%
19/25
43.2%/56.8%
0.005166/72
69.7%/30.3%
78/122
39%/61%
<0.001
Hashimoto’s thyroiditis, present/absent10/98
9.2%/90.8%
4/40
9.1%/90.9%
1.043/195
18.1%/81.9%
44/156
22%/78%
0.304
TSH, μIU/mL, M (range)1.75 (0.07–7.27)1.45 (0.07–5.79)0.5892.12 (0.07–26.5)1.96 (0.07–28.3)0.586
T4, μg/dL, M (range)8.34 (4.68–13.2)7.86 (5.25–12)0.0268.03 (4.36–24.4)8.17 (3.3–15.1)0.892
T3, ng/mL, M (range)1.39 (0.82–2.55)1.42 (0.8–1.94)0.1491.34 (0.5–2.48)1.33 (0.63–2.28)0.823
TGAB, %, M (range)3.84 (2.53–51.3)3.51 (2.45–43.1)0.4234.79 (1.98–62.6)4.39 (1.82–63.7)0.408
TMAB, %, M (Range)2.96 (1.9–39.8)2.98 (1.69–29.7)0.6543.61 (1.53–41.7)3.32 (2.01–44)0.237
Ultrasonographic characteristics of suspicious nodules
Tumor size (≦1 cm/>1 cm)22/86
20.4%/79.6%
13/31
29.5%/70.5%
0.32838/200
16%/84%
66/134
33%/67%
<0.001
Multifocal/unifocal50/58
46.3%/53.7%
14/30
31.8%/68.2%
0.10117/121
49.1%/50.9%
78/122
39%/61%
0.05
Bilateral/unilateral32/76
29.6%/70.4%
10/34
22.7%/77.3%
0.38878/160
32.8%/67.2%
56/144
28%/72%
0.280
Margin (regular/irregular)36/65
35.6%/64.4%
24/19
55.8%/44.2%
0.01293/129
41.9%/58.1%
86/99
46.5%/53.5%
0.352
Border (clear/obscure)51/52
49.5%/50.5%
24/17
58.5%/41.5%
0.488112/116
49.1%/50.9%
102/91
52.8%/47.2%
0.446
Hypoechoic/Hyper or isoechoic calcification98/8
90.7%/9.3%
41/2
95.3%/4.7%
0.724227/11
95.4%/4.6%
191/9
95.5%/4.5%
0.951
Non-/micro-/coarse calcification18/73/17
16.7%/67.6%/15.7%
9/32/3
20.4%/72.7%/6.9%
0.32235/170/31
14.8%/72%/13.2%
57/108/35
28.5%/54%/17.5%
<0.001
Vascularization
None/low/middle/high
0/28/26/25
0/35.4%/32.9%/31.7%
1/14/11/8
2.9%/41.2%/32.4%/23.5%
0.43412/71/61/34
6.7%/39.9%/34.3%/19.1%
13/61/57/21
8.6%/40.1%/37.5%/13.8%
0.579

CLNM: central lymph node metastases; NCLNM: central lymph node metastases negative; PTC: papillary thyroid cancer.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.